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dle-aged patients. LP was first described by 
Erasmus Wilson in 1869; it presents with a 
variety of clinical manifestations affecting 
the skin, mucous membranes, nails and hair 
 [1] . Nail involvement occurs in 10% of pa-
tients, in approximately 4% with perma-
nent damage to at least one nail. The nails 
may also be affected in the absence of cuta-
neous symptoms such as destructive in-
flammatory onychodystrophy  [2, 3] . LP of 
the nail affects the quality of life consider-
ably. Treatment of nail LP is difficult and an 
optimal therapy is lacking. We report 2 cas-
es of nail LP that were successfully treated 
with alitretinoin. Using PubMed, a review 
of the English literature revealed one case 
report of nail LP treated with alitretinoin  [4] 
and another case of oral, esophageal and cu-
taneous LP controlled with alitretinoin that 
also showed nail improvement  [5] . Our ob-
jective is to report additional cases to the 
scant existing literature to learn more about 
therapeutic options for nail LP.
 Case Reports 
 Case 1 
 A man in his 50s reported a 30-month 
history of mucous membrane and nail 
changes. His past medical history was non-
contributory and he was not on any regu-
lar systemic medication. Clinical examina-
tion showed an involvement of all finger-
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 Abstract 
 Background: Treatment of nail lichen planus 
(LP) is difficult and an optimal therapy is lack-
ing.  Objective: To report additional cases to 
the scant existing literature to learn more 
about therapeutic options for nail LP.  Meth-
ods: A regimen of 30 mg alitretinoin daily in 
2 cases of nail LP over a period of 9 and 8 
months, respectively.  Results: In either case, 
nail changes showed marked improvement 
under oral alitretinoin therapy within 2 and 4 
months, respectively. In both patients, affect-
ed nails with end-stage destructive pterygi-
um were resistant to any previously applied 
therapy.  Conclusion: Alitretinoin is an effec-
tive treatment option for nail LP. We recom-
mend early diagnosis of nail LP and early ini-
tiation of systemic therapy with alitretinoin 
to prevent the development of pterygium 
and permanent nail damage. However, fur-
ther clinical studies are needed to establish 
reliable guidelines for nail LP therapy. 
 © 2014 S. Karger AG, Basel 
Introduction
 Lichen planus (LP) is a common chron-
ic inflammatory mucocutaneous condition 
of unknown origin that usually affects mid-
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nails and toenails with onychodystrophy, 
discoloration, longitudinal ridging, stria-
tions, splitting and thinning, some nails 
also exhibited pterygium ( fig. 1 a). Myco-
logical examination of the nail was nega-
tive. The diagnosis of LP with oral and nail 
involvement was made based on these 
clinical features. Oral lesions were treated 
with topical corticosteroids and showed 
good clinical response. Nail involvement 
showed resistance to the topical applica-
tion of high-potency corticosteroids and 
tacrolimus 0.1% ointment. After 5 months, 
oral alitretinoin 30 mg/day was initiated, 
which led to a significant improvement of 
most nails. The nail changes began to re-
solve within 2 months after alitretinoin ad-
ministration. Alitretinoin therapy contin-
ued over a total period of 9 months and 
was well tolerated with no side effects.
A significant improvement of most nails 
was observed after 5 months of therapy 
( fig.  1 b). Affected nails with pterygium 
showed resistance to therapy. Follow-up 
over 1 year revealed a stable nail condition 
under topical mometasone solution to 
maintain the effect of alitretinoin therapy.
 Case 2 
 A woman in her 60s with a 27-year his-
tory of LP presented with typical lesions on 
the skin, oral cavity and nails. Except for 
multiple allergies (type I hypersensitivity) 




















   
   
   
   
   
   
   
   
   
   
   


























ism, her past medical history was noncon-
tributory. Clinical examination showed in-
volvement of all fingernails and toenails 
with severe onycholysis and onychodys-
trophy, chromonychia with yellow-brown 
discoloration, longitudinal ridging, stria-
tions, splitting and thinning, some nails 
showing severe pterygium ( fig. 1 c). There 
were also typical skin changes on the pa-
tient’s arms with mucous membrane in-
volvement. The result of a skin biopsy was 
consistent with LP ( fig. 2 ). Mycological ex-
amination of the nails was negative. The 
diagnosis of nail LP was made based on 
clinical appearance and skin histology. 
Treatment with topical applications of 
corticosteroids resulted in a significant im-
provement of the skin and oral lesions but 
without any effect on the nails. Tacrolimus 
0.1% ointment was also applied to the nails 
without any clinical improvement. Treat-
ment with oral alitretinoin 10 mg/day was 
started, which was increased to 30 mg/day 





 Fig. 1. Two cases of nail LP managed with 
alitretinoin: prior to oral administration of 
alitretinoin with resistance to topical treat-
ment ( a ,  c ) and after treatment with alitre-





























 Fig. 2. Histology from a skin biopsy of the 
second case demonstrates classic features 
of LP such as orthohyperkeratosis, wedge-
shape hypergranulosis, acanthosis with a 
sawtooth rete ridge pattern, band-like lym-
phoid infiltrate with interface destruction 
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for a total of 8 months. The nail changes 
improved after alitretinoin administration 
within 4 months ( fig. 1 d), and the patient’s 
thyroid hormone levels remained normal. 
However, since the patient complained of 
headache, elevated liver enzymes and ab-
dominal pain that later developed into 
acute diverticulitis, treatment with alitre-
tinoin was discontinued, which led to 
worsening of her cutaneous LP and was 
managed by topical corticosteroids. Her 
nail LP was stable although pterygium re-
mained resistant to therapy. The patient 
refused to adhere to long-term follow-up.
 Discussion 
 Here we report on 2 cases of nail LP 
involving all nails that were successfully 
treated with oral alitretinoin, adding them 
to one previous case report by Pinter et al. 
 [4] . The typical clinical features in each 
case and histologic features of a skin bi-
opsy in the second case were diagnostic of 
nail LP. Nail LP affects the quality of life 
considerably due to impaired manual ac-
tivity, cosmetic discomfort, the chronic 
course of the disease and numerous recur-
rences. Different treatment modalities 
have been used in nail LP: although they 
are usually ineffective, topical corticoste-
roids are commonly considered as first-
line treatment for nail LP. For involve-
ment of up to three nails, intralesional ste-
roid injections can be considered, but are 
very painful and relapses are common  [3] . 
If more than three nails are involved, sys-
temic corticosteroids are considered as 
first-line treatment; however, prolonged 
or repeated use may cause considerable 
side effects  [6, 7] . There is a single case re-
port of using tacrolimus ointment suc-
cessfully in nail LP  [8] . Another report of 
a patient with refractory nail LP showed 
significant improvement after etanercept 
monotherapy  [9] , although some studies 
described etanercept as a trigger factor for 
LP  [10] . In 2 patients, LP involving the 
nails improved with methotrexate (10–20 
mg subcutaneously once weekly) a few 
weeks after initiation  [11] . Etretinate and 
antimalarials were also reported  [12, 13] . 
Although acitretin is a known treatment 
modality for LP, an effect on nail LP is 
lacking  [14] . No curative therapy is known 
and the treatment of nail LP is challenging 
due to the lack of treatment guidelines. 
Frequent relapses are common. Autoim-
mune hypothyroidism may contribute to 
the development of LP with a possible un-
derlying associated mechanism  [15] . In-
formation about the efficacy of systemic 
treatments in nail LP is scarce because 
most studies on LP did not focus on nail 
changes. Alitretinoin (9- cis -retinoic acid) 
is an endogenous vitamin A derivative 
which regulates cell proliferation and dif-
ferentiation. Its anti-inflammatory and 
immune-modulating effects result from 
the control of pro-inflammatory cytokine 
production by keratinocytes and modula-
tion of leukocyte activity. Therefore, it has 
been approved for the oral treatment of 
moderate to severe chronic hand eczema 
that is unresponsive to potent topical cor-
ticosteroids  [16] . The benefit of systemic 
retinoids for LP is supposed to result from 
their antiproliferative mode of action me-
diated by binding to nuclear receptors 
(RAR and RXR) and there is some evi-
dence of receptor expression in the nail 
matrix  [4] . The positive effect of alitre-
tinoin on skin, oral, esophageal and nail LP 
has already been described  [5] . In our 2 
cases, the patients showed nail LP which 
was refractory to classic treatment options 
(topical corticosteroid and tacrolimus 
ointment 0.1%). We therefore chose a reg-
imen of 30 mg alitretinoin daily in both 
cases over a period of 9 and 8 months, 
respectively. In the second case, the pa-
tient did not tolerate systemic alitretinoin 
30 mg daily and developed systemic side 
effects as well as acute abdominal symp-
toms which were most likely unrelated to 
alitretinoin. However, dose adjustment 
would be an option after stabilizing her 
acute symptoms. The patient was not 
compliant enough for long-term follow-
up. In either case, nail changes showed 
marked improvement under oral alitre-
tinoin therapy within 2 and 4 months, re-
spectively. In both patients, affected nails 
with end-stage destructive pterygium 
were resistant to any applied therapy. To-
gether, the significant clinical improve-
ment in our 2 cases suggests that alitre-
tinoin is an effective treatment option for 
nail LP. We recommend early diagnosis of 
nail LP and early initiation of systemic 
therapy with alitretinoin to prevent the 
development of pterygium and perma-
nent nail damage. However, further clini-
cal studies are needed to establish reliable 
guidelines for nail LP therapy as well as an 
improved scoring system for nail LP to as-
sess treatment efficacy.
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